ArticleCurrent microbiology2011
Chitosan-EDTA new combination is a promising candidate for treatment of bacterial and fungal infections.
Article in Current microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 62 citations in OpenAlex.
- EDTA enhances antimicrobial activity of PR-39 and Protegrin-1 antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa in serum.Folia microbiologica · 2026Article
- Advances in Chitosan Derivatives: Preparation, Properties and Applications in Pharmacy and Medicine.Gels (Basel, Switzerland) · 2024Review
- Novel Fabrication of Bio-polymeric Nanogel Loaded with Nalidixic Acid Formulations for the Effective Prevention of Bacterial Pathogens Leading Urinary Tract Infection and Its Biosafety Evaluation.Current microbiology · 2024Article
- Article
- Tetrasodium EDTA for the prevention of urinary catheter infections and blockages.RSC advances · 2023Article
- EDTA-chitosan is a feasible conditioning agent for dentin bonding.Clinical oral investigations · 2022Article
- Nanotechnology Fundamentals Applied to Clinical Infectious Diseases and Public Health.Open forum infectious diseases · 2021Review
- An overview of chitosan and its application in infectious diseases.Drug delivery and translational research · 2021Review
- Article
- Article
- Resveratrol, pterostilbene, and baicalein: plant-derived anti-biofilm agents.Folia microbiologica · 2018Article
- Dual function of EDTA with silver nanoparticles for root canal treatment-A novel modification.PloS one · 2018Article
- Comparison of the Antimicrobial Properties of Chitosan Oligosaccharides (COS) and EDTA against Fusarium fujikuroi Causing Rice Bakanae Disease.Current microbiology · 2016Article
- Fabrication and In Vitro/In Vivo Performance of Mucoadhesive Electrospun Nanofiber Mats Containing α-Mangostin.AAPS PharmSciTech · 2015Article
- Electrospun chitosan/polyvinyl alcohol nanofibre mats for wound healing.International wound journal · 2014Article
- Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens.The Journal of investigative dermatology · 2013Article
- Antibiofilm activity of ultrasonic and diode laser activated sodium hypochlorite, chitosan, and chlorhexidine: A confocal laser scanning microscopicJournal of conservative dentistry and endodonticsArticle
- Effect of chitosan-ethylenediamine tetraacetic acid on Enterococcus faecalis dentinal biofilm and smear layer removal.Journal of conservative dentistry : JCDArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan is an attractive preparation widely used as a pharmaceutical excipient. This study aimed to evaluate the antimicrobial activities of chitosan derivatives, EDTA, and the newly developed chitosan-EDTA combination against Gram-negative and Gram-positive bacteria as well as Candida albicans. Antimicrobial activity was studied. Both minimal Inhibitory Concentrations (MIC) and minimal biocidal concentrations (MBC) were determined. Chitosan acetic acid recorded lower MIC values against Enterococcus faecalis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans than those exhibited by EDTA. EDTA failed to have inhibitory activity against Enterococcus faecalis as well as MBC against any of the studied microorganisms. Chitosan acetic acid's MBC were recorded to all examined species. Checkerboard assay results indicated a synergistic antimicrobial activity of the new combination against Staphylococcus aureus and an additive effect against other microorganisms. Moreover, a short microbial exposure to chitosan-EDTA (20-30 min) caused complete eradication. Due to the continuous emergence of resistant strains, there is an urgent need to discover new antimicrobial agents. Our findings suggest the use of chitosan as an enhancing agent with antibacterial and antifungal properties in combination with EDTA in pharmaceutical preparations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.